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CHEMICAL AND MOLECULAR CONJUGATES I
simultaneously. Thus, arsonium-containing cationic lipids appear 
as promising versatile multi-faceted agents that could fi nd various 
applications for the treatment of inherited as well as acquired diseases.
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Methacrylate polymers have been described as highly biocompatible 
and are successfully used in medical applications1. Due to their 
cationic nature, these polymers can be used to form polyplexes with 
DNA for its delivery. This work aims to understand how feasible 
pDMAEMA (poly(2-(N,N’-dimethylamino)ethyl methacrylate)) is 
as a non viral gene delivery system to the retina. pDMAEMA-DNA 
polyplexes were prepared in PBS at 5, 7.5, 10, 12.5 and 20 nitrogen/
phosphorous (N/P) ratio. Dynamic light scattering and zeta potential 
measurements confi rmed positively charged nanosized polyplexes for 
all ratios. pDMAEMA was able to effi ciently complex and protect 
DNA from DNase I degradation. The cytotoxicity was evaluated 
using two retinal pigment epithelium (RPE) cell lines: ARPE-19 
and D407 and the HEK293 cell line (control). We have found that 
cytotoxicity of the uncomplexed polymer is concentration and time 
dependent, as expected, and negligible for the pDMAEMA-DNA 
polyplexes. Furthermore, for the concentrations to be used in vivo, the 
cytotoxicity was negligible, as shown by the absence of infl ammation 
upon injection in the subretinal space of C57Bl6 mice. Transfection 
efficiency, as evaluated by fluorescence microscopy and flow 
cytometry, showed that the retinal cell lines were in fact transfected 
by these polyplexes, with the effi ciency varying according to the ratio 
of N:P. These results suggest that pDMAEMA is a feasible candidate 
for non-viral gene delivery to the retina. 1. Ji Hoon Jeong, Sung Wan 
Kim, Tae Gwan Park (2007). Molecular design of functional polymers 
for gene therapy. Progress in Polymer Science, Volume 32, Issue 11: 
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Our goal is to develop chitosan-based non-viral vectors optimized 
for ocular gene therapy. Therefore, chitosan-DNA polyplexes were 
prepared using a NH3:PO4 ratio of 5:1. These polyplexes were 
characterized regarding their morphology, stability and transfection 
effi ciency on retinal pigment epithelial cells. The method to produce 
the polyplexes proved to be reproducible, consistently yielding 
polyplexes with a spherical morphology and sizes below 500 
nm. These polyplexes have long-term stability and are capable of 
effi ciently protecting DNA from DNase I degradation. However, 
transfection effi ciency, evaluated by fl uorescence microscopy and 
fl ow cytometry, showed these polyplexes to fall below commercial 
transfection reagents. The lower transfection effi ciency observed 
for chitosan-DNA polyplexes is most likely due to reduced cell 
penetration and defi cient plasmid release. Our endeavor to improve 
this lower transfection effi ciency encompassed the preparation of 
polyplexes with different NH3:PO4 ratios and combining these 
with hyaluronic acid. The results for these hybrid polyplexes show 
a marked increase in the transfection effi ciency. In addition, we are 
studying the effect of chemical modifi cation of chitosan to promote 
timely and effi cient DNA release. Overall, our hybrid systems show 
an improvement of the effi ciency of chitosan-based nonviral vectors 
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microRNAs cannot be directly applied for clinical use in that they 
can be rapidly degraded and their cellular internalization is poor due 
to its negative surface charge. A variety of delivery systems, either 
viral or non-viral, have been investigated for microRNA delivery. 
Non-viral vectors have received growing interests due to many 
advantages such as they offer over the viral counterparts including 
improved safety, low immune responses, enabling repeated uses, and 
ease of production. In this report, an anionic natural polysaccharide-
chondroitin sulphate (CS) was chemically linked to polyethylenimine 
(PEI) with a lower molecular weight of 10 kDa to minimize its 
cytotoxicity as a microRNA carrier for the treatment of ischemia 
stroke. It is noted the cytotoxicity of PEI reduced dramatically after 
modifi cation as compared to the original PEI of molecular weight 
of 10K and 25K Da. The TEM image of CS-PEI and miRNA shows 
a spherical structure with a uniform size distribution. The size falls 
in a perfect range (about 100 nm), larger enough to escape the renal 
fi ltration (< 10 nm) but smaller enough to prevent uptake by the 
reticuloendothelial system (> 200 nm).
